Chronic pain affects a substantial proportion of cancer patients at every stage of disease, yet it remains undertreated partly because clinicians and researchers have historically treated it as a single, monolithic problem. A comprehensive primer in Nature Reviews Disease Primers reframes cancer pain as a collection of mechanistically distinct syndromes — a reclassification with real implications for how oncologists, pain specialists, and patients approach management across the entire cancer continuum, including survivorship.
The primer identifies several converging biological pathways that drive cancer-associated pain. Beyond classical peripheral nociception, the framework emphasizes central sensitization — a state of heightened spinal and supraspinal excitability — and maladaptive neuroplasticity as major contributors to pain chronification. Notably, non-neuronal cells emerge as central players: tumor-infiltrating immune cells, Schwann cells in peripheral nerves, and central glial populations (astrocytes and microglia) actively modulate nociceptive signaling rather than serving merely as bystanders. Sex hormones add another layer of complexity, influencing baseline pain thresholds, susceptibility to treatment-related neuropathy, and differential analgesic responses between male and female patients. The proposed assessment framework integrates quantitative sensory testing with psychosocial screening to capture this biological and psychological heterogeneity.
This mechanistic granularity matters because it directly challenges the still-common clinical reflex of escalating opioid dosing as the default response to refractory cancer pain. If glial neuroinflammation or Schwann-cell pathology underlies a patient's pain phenotype, opioids address symptoms without touching the underlying biology. The primer's emphasis on precision phenotyping — pairing biomarker-driven patient stratification with targeted non-opioid and adjuvant agents — aligns with a growing body of translational research suggesting that mechanism-matched therapies may outperform one-size-fits-all analgesic ladders. Key limitations remain: most mechanistic insights derive from preclinical models, and large randomized trials validating biomarker-guided pain management in oncology are still sparse. Nevertheless, for a field where the WHO analgesic ladder dates to 1986, this synthesis represents a potentially practice-shifting reconceptualization rather than incremental refinement.